Logo

Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study for Steroid-Refractory Acute Graft-Versus-Host Disease (aGvHD)

Share this

Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study for Steroid-Refractory Acute Graft-Versus-Host Disease (aGvHD)

Shots:

  • The P-III (NCT02524847) study involves assessing of Therakos + methoxsalene in 25 pediatric patients with aGvHD aged 1 yr to 21 yrs. @4-12 wks.
  • The P-III study resulted in general response rates @4-12 wks. (74%- 48%-) with OR exceeding the target rates in mid-term study
  • Therakos Immunotherapy is delivered using CELLEX system for the treatment of skin manifestations in CTCL used in almost 25 countries

Ref: PRNewsWire | Image: WSJ

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions